Former Union health minister Harsh Vardhan holds up a vial of Covaxin, at AIIMS New Delhi. Photo: Reuters/Adnan Abidi
- The latest study assessed 2,714 hospital workers at AIIMS Delhi from April 15 May 15, and who had symptomatic COVID-19.
- Researchers noted that the delta variant was the dominant strain in India in the study period, accounting for about 80% of all confirmed cases.
- The study found that the vaccine’s effectiveness against symptomatic COVID-19 after two doses, with the second dose administered 14+ days before an RT-PCR test, was 50%.
New Delhi: Two doses of Covaxin are 50% effective against symptomatic disease, according to the first real-world assessment of India’s indigenous COVID-19 vaccine published in The Lancet Infectious Diseases journal.
(Editor’s note: A vaccine’s efficacy represents the level of protection it confers in a large clinical trial. Its effectiveness refers to the level of protection it confers in the real-world. Whereas the efficacy denotes the theoretical maximum, the effectiveness is its translation to messy real-world situations.)
Results of an interim study recently published in The Lancet showed that two doses of Covaxin, also known as BBV152, had 77.8% efficacy against symptomatic disease and presented no serious safety concerns.
The latest study assessed 2,714 hospital workers at the All India Institute of Medical Sciences (AIIMS) in Delhi, from April 15 May 15, who were symptomatic and underwent RT-PCR test for COVID-19 detection.
Researchers noted that the delta variant was the dominant strain in India during the study period, accounting for approximately 80% of all confirmed COVID-19 cases.
Covaxin, developed by Hyderabad-based Bharat Biotech in collaboration with the National Institute of Virology, Pune, is an inactivated whole virus vaccine administered in a two-dose regimen, 28 days apart.
In January this year, Covaxin was approved for emergency use in India for people aged 18 and above. The WHO added the vaccine to its list of approved emergency use COVID-19 vaccines earlier this month.
The latest study was conducted during India’s second COVID-19 surge and in healthcare workers who were primarily offered Covaxin.
“Our study offers a more complete picture of how BBV152 (Covaxin) performs in the field and should be considered in the context of COVID-19 surge conditions in India, combined with the possible immune evasive potential of the Delta variant,” said Manish Soneja, Additional Professor of Medicine at AIIMS New Delhi.
“Our findings add to the growing body of evidence that rapid vaccine rollout programmes remain the most promising path to pandemic control while public health policies must continue to include additional protective measures, such as mask-wearing and social distancing,” Soneja said in a statement.
The COVID-19 vaccination centre at AIIMS New Delhi exclusively offered Covaxin beginning January 16 this year to all of its 23,000 employees.
Researchers evaluated the effectiveness of the vaccine against symptomatic RT-PCR confirmed SARS-CoV-2 infection.
Of the 2,714 employees in the study population, 1,617 people tested positive for SARS-CoV-2 infection, the virus that causes COVID-19, and 1,097 tested negative.
Positive cases were matched to negative RT-PCR tests (controls).
The odds of vaccination with Covaxin were compared between cases and controls and adjusted for occupational exposure to COVID-19, previous SARS-CoV-2 infection, and infection dates.
The study found that the vaccine effectiveness against symptomatic COVID-19 after two doses of Covaxin with the second dose administered 14 or more days before undergoing RT-PCR testing was 50%.
The effectiveness of two vaccine doses remained stable over the seven-week follow-up period, the researchers said.
The adjusted vaccine effectiveness of the first dose, estimated after seven and 21 days, was low, which is consistent with the performance of other preventives against the Delta variant, they said.
“Findings from the study confirm previous research indicating that two doses of BBV152 are required to achieve maximum protection and that all vaccine roll-out plans must follow the recommended dosing schedule,” said Parul Kodan, Assistant Professor of Medicine at AIIMS New Delhi.
“More research is needed to better understand how these findings translate to BBV152’s effectiveness against delta and other variants of concern, especially related to severe COVID-19 infection, hospitalisation, and deaths,” Kodan said.
The authors acknowledge that the vaccine effectiveness of Covaxin estimated in this study is lower than the efficacy reported by the recently published phase 3 trial. They noted that several factors may be responsible for the lower vaccine effectiveness in the latest study.
The researchers said this study population only included hospital employees who may have a higher risk of exposure to COVID-19 infection than the general population.
The research was conducted during the peak of India’s second wave of COVID-19 with high test positivity rates for both hospital employees and residents of Delhi, they said.
Prevalence of circulating variants of concern, especially the delta variant, may have also contributed to the vaccine’s lower effectiveness, according to the researchers.
The authors acknowledge several limitations to their study. For one, the study does not estimate the vaccine’s effectiveness against hospitalisation, severe diseas, and death, which require further assessment, they noted.
Also, the study was not designed to estimate vaccine effectiveness for different time intervals after vaccination or to determine if its value changed over time, the researchers added.